Greater dimensions in the fraud with cancer drugs?

Pharmacists: Greater dimensions in the fraud with cancer drugs? Is the fraud of pharmacists with cancer drugs in Germany but larger than expected? According to the broadcaster NDR Info, the public prosecutor's office in Mannheim still investigates employees of a pharmaceutical manufacturer. Furthermore, the prosecutor determined Braunschweig against a pharmacist, which is said to have implemented 1.6 million euros.

(21.04.2010) Is the fraud of pharmacists with cancer drugs in Germany is bigger than expected? According to the broadcaster NDR Info, the public prosecutor's office in Mannheim still investigates employees of a pharmaceutical manufacturer. Furthermore, the prosecutor determined Braunschweig against a pharmacist, which is said to have implemented 1.6 million euros.

According to information from NDR Info, the pharmaceutical manufacturer Sanofi-Aventis reportedly filed a complaint in late 2016 in Mannheim for violations of patent and trademark laws. Another pharmaceutical manufacturer is said to have brought medicines from abroad to Germany and distributed them here. That is also the reproach, which stands for a few days against about 70 German pharmacists in the room. They are said to have marketed Krebsmittel- so-called cytostatic drugs with the same mesh, which were probably also effective to have been ineffective. Between the two investigations, according to the prosecutor in Mannheim, Christina Arnold, connections exist.

Apart from possible health damages, which cancer patients can suffer by ineffective means, the statutory health insurance companies and the pharmaceutical company Sanofi-Aventis have suffered financial damage. Because the pharmacists are said to have procured cheap foreign ingredients for cancer drugs in the past and accounted for at the cashier at the more expensive usual tariff. The Techniker Krankenkasse (TK) and the AOK Lower Saxony estimated the resulting damage to a "double-digit million amount". (TF)